Ideaya Biosciences, INC Form 4 insider transactions

Director Terry J. Rosen of Ideaya Biosciences reports the acquisition of stock options.

Susan L. Kelley, a director at Ideaya Biosciences, exercised stock options to acquire 16,200 shares of common stock on May 31, 2024.

Malcolm Garret Hampton, a director of Ideaya Biosciences, acquired stock options for 16,200 shares at an exercise price of $36.55 on May 31, 2024.

Director Jeffrey Stein acquired stock options in Ideaya Biosciences, Inc. on May 31, 2024.

Director Scott W. Morrison acquired stock options in Ideaya Biosciences, Inc. on May 31, 2024.

Director Wendy L. Yarno of Ideaya Biosciences reports the acquisition of stock options.

Director Catherine J. Mackey exercised stock options to acquire 16,200 shares of Ideaya Biosciences common stock on May 31, 2024.

Michael Anthony White, Chief Scientific Officer of Ideaya Biosciences, exercised stock options and sold shares on May 29, 2024, according to a recent SEC filing.

IDEAYA Biosciences CEO Yujiro Hata exercised stock options and sold shares of common stock between May 14 and May 16, 2024, under a pre-arranged Rule 10b5-1 trading plan.

IDEAYA Biosciences CEO, Yujiro Hata, acquired 480,000 stock options on March 1, 2024, according to a Form 4 filing.

Andres Ruiz Briseno, SVP, Head of Finance and Investor Relations at Ideaya Biosciences, acquired stock options for 85,000 shares on March 1, 2024.

Darrin Beaupre, Chief Medical Officer of Ideaya Biosciences, acquired stock options for 160,000 shares on March 1, 2024.

Michael Anthony White, Chief Scientific Officer of Ideaya Biosciences, acquired stock options for 140,000 shares on March 1, 2024.

Jason Throne, Chief Legal Officer of Ideaya Biosciences, acquired stock options for 125,500 shares on March 1, 2024.